Literature DB >> 22772448

Why the structure but not the activity of the immunoproteasome subunit low molecular mass polypeptide 2 rescues antigen presentation.

Michael Basler1, Christoph Lauer, Jacqueline Moebius, Reinhold Weber, Michael Przybylski, Alexei F Kisselev, Christopher Tsu, Marcus Groettrup.   

Abstract

The proteasome is responsible for the generation of most epitopes presented on MHC class I molecules. Treatment of cells with IFN-γ leads to the replacement of the constitutive catalytic subunits β1, β2, and β5 by the inducible subunits low molecular mass polypeptide (LMP) 2 (β1i), multicatalytic endopeptidase complex-like-1 (β2i), and LMP7 (β5i), respectively. The incorporation of these subunits is required for the production of numerous MHC class I-restricted T cell epitopes. The structural features rather than the proteolytic activity of an immunoproteasome subunit are needed for the generation of some epitopes, but the underlying mechanisms have remained elusive. Experiments with LMP2-deficient splenocytes revealed that the generation of the male HY-derived CTL-epitope UTY(246-254) was dependent on LMP2. Treatment of male splenocytes with an LMP2-selective inhibitor did not reduce UTY(246-254) presentation, whereas silencing of β1 activity increased presentation of UTY(246-254). In vitro degradation experiments showed that the caspase-like activity of β1 was responsible for the destruction of this CTL epitope, whereas it was preserved when LMP2 replaced β1. Moreover, inhibition of the β5 subunit rescued the presentation of the influenza matrix 58-66 epitope, thus suggesting that a similar mechanism can apply to the exchange of β5 by LMP7. Taken together, our data provide a rationale why the structural property of an immunoproteasome subunit rather than its activity is required for the generation of a CTL epitope.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772448     DOI: 10.4049/jimmunol.1103592

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  mTORC1 Coordinates Protein Synthesis and Immunoproteasome Formation via PRAS40 to Prevent Accumulation of Protein Stress.

Authors:  Young Sung Yun; Kwan Hyun Kim; Barbara Tschida; Zohar Sachs; Klara E Noble-Orcutt; Branden S Moriarity; Teng Ai; Rui Ding; Jessica Williams; Liqiang Chen; David Largaespada; Do-Hyung Kim
Journal:  Mol Cell       Date:  2016-02-11       Impact factor: 17.970

2.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

3.  Oxathiazolones Selectively Inhibit the Human Immunoproteasome over the Constitutive Proteasome.

Authors:  Hao Fan; Nicholas G Angelo; J David Warren; Carl F Nathan; Gang Lin
Journal:  ACS Med Chem Lett       Date:  2014-02-03       Impact factor: 4.345

4.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

5.  Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.

Authors:  Henry W B Johnson; Janet L Anderl; Erin K Bradley; John Bui; Jeffrey Jones; Shirin Arastu-Kapur; Lisa M Kelly; Eric Lowe; David C Moebius; Tony Muchamuel; Christopher Kirk; Zhengping Wang; Dustin McMinn
Journal:  ACS Med Chem Lett       Date:  2017-03-09       Impact factor: 4.345

Review 6.  Recent insights how combined inhibition of immuno/proteasome subunits enables therapeutic efficacy.

Authors:  Michael Basler; Marcus Groettrup
Journal:  Genes Immun       Date:  2020-08-25       Impact factor: 2.676

Review 7.  Subunit specific inhibitors of proteasomes and their potential for immunomodulation.

Authors:  Alexei F Kisselev; Marcus Groettrup
Journal:  Curr Opin Chem Biol       Date:  2014-09-15       Impact factor: 8.822

Review 8.  [Research progress on selective immunoproteasome inhibitors].

Authors:  Limin Kong; Jingyi Lu; Huajian Zhu; Jiankang Zhang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-12-25

9.  Ubiquitin-independent proteosomal degradation of myelin basic protein contributes to development of neurodegenerative autoimmunity.

Authors:  Alexey Belogurov; Ekaterina Kuzina; Anna Kudriaeva; Alexey Kononikhin; Sergey Kovalchuk; Yelena Surina; Ivan Smirnov; Yakov Lomakin; Anna Bacheva; Alexey Stepanov; Yaroslava Karpova; Yulia Lyupina; Oleg Kharybin; Dobroslav Melamed; Natalia Ponomarenko; Natalia Sharova; Eugene Nikolaev; Alexander Gabibov
Journal:  FASEB J       Date:  2015-01-29       Impact factor: 5.191

10.  Immunoproteasome deficiency modifies the alternative pathway of NFκB signaling.

Authors:  Marcela Maldonado; Rebecca J Kapphahn; Marcia R Terluk; Neal D Heuss; Ching Yuan; Dale S Gregerson; Deborah A Ferrington
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.